Adamas Pharmaceuticals (ADMS) Downgraded by JMP Securities to Market Perform

Adamas Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Adamas Pharmaceuticals Downgraded by JMP Securities on 10/11/2021. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of N/A.

Shares of Adamas Pharmaceuticals traded up $3.46 on Monday, reaching $8.07. 32303148 shares of the stock traded hands, compared to its average volume of 145199. Shares of Adamas Pharmaceuticals were trading at $8.07 on Monday. The firm’s 50 day moving average is $4.78 and its 200 day moving average is $5.07.Adamas Pharmaceuticals has a 12 month low of $7.90 and a 12 month high of $9.15. While on yearly highs and lows, Adamas Pharmaceuticals’s today has traded high as $8.10 and has touched $7.90 on the downward trend. See More Analyst Rating at: RATING

Adamas Pharmaceuticals Earnings and What to expect: 

Adamas Pharmaceuticals last announced its earnings results on August 8th, 2021. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The business had revenue of $21.97 million for the quarter, compared to analysts’ expectations of $22.24 million. Adamas Pharmaceuticals has generated ($2.03) earnings per share over the last year (($1.69) diluted earnings per share). Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.01) to ($0.45) per share. Adamas Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.01) to ($0.45) per share. The P/E ratio of Adamas Pharmaceuticals is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Adamas Pharmaceuticals is -4.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Adamas Pharmaceuticals (ADMS) Moving Average Technical Analysis

5 day Moving Average is $5.28 And 5 day price change is $3.43 (73.92%)  with average volume for 5 day average is 6,531,580. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.96 and 20 day price change is $3.51 (76.97%) and average 20 day moving volume is 1,761,090. 50 day moving average is $4.78  and 50 day price change is $3.29 ( 68.83%)  and with average volume for 50 days is : 853,914. 200 day moving average is $5.07  and 200 day price change is $3.49 (76.20%)  and with average volume for 200 days is : 576,997.

Other owners latest trading in Adamas Pharmaceuticals :

  • On 8/23/2021 shares held by Morgan Stanley were 73,233 which equates to market value of $0.39M and appx 0.00% owners of Adamas Pharmaceuticals
  • On 8/17/2021 shares held by Worth Venture Partners LLC were 590,730 which equates to market value of $3.12M and appx 1.20% owners of Adamas Pharmaceuticals
  • On 8/17/2021 shares held by Price T Rowe Associates Inc. MD were 33,700 which equates to market value of $0.18M and appx 0.00% owners of Adamas Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 71.69% for Adamas Pharmaceuticals

See More Analyst Rating at: RATING